“If you want to make money, really follow your passion rather than follow the money, because the money later on will come.”
​
In this episode of The Biotech Startups Podcast, Dr. Judy Chou shares her journey as employee number one at Tanvex, walking into an empty 50,000 square foot facility and building a biosimilar company from scratch after a close friend’s death from metastatic lung cancer reshaped her understanding of drug access and affordability. She recounts an extraordinary FDA meeting where, as the sole company representative, she fielded questions from 32 regulators and ultimately convinced them to waive all preclinical animal studies, then later took on unexpected responsibility for building three manufacturing suites when multiple VPs were fired. The conversation also follows her move to Medivation, where she scaled technical operations from two people to a global network of over 50 CDMOs and CROs, culminating in a high-stakes bidding war among five pharma giants that ended with Pfizer acquiring Medivation for $14.3 billion, up from a $9 billion market cap just three months earlier.
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a
TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today:
https://www.excedr.com/partners.
“If you want to make money, really follow your passion rather than follow the money, because the money later on will come.”
In this episode of The Biotech Startups Podcast, Dr. Judy Chou shares her journey as employee number one at Tanvex, walking into an empty 50,000 square foot facility and building a biosimilar company from scratch after a close friend’s death from metastatic lung cancer reshaped her understanding of drug access and affordability. She recounts an extraordinary FDA meeting where, as the sole company representative, she fielded questions from 32 regulators and ultimately convinced them to waive all preclinical animal studies, then later took on unexpected responsibility for building three manufacturing suites when multiple VPs were fired. The conversation also follows her move to Medivation, where she scaled technical operations from two people to a global network of over 50 CDMOs and CROs, culminating in a high-stakes bidding war among five pharma giants that ended with Pfizer acquiring Medivation for $14.3 billion, up from a $9 billion market cap just three months earlier.
Key topics covered:
- Biosimilars and Access: Why Judy shifted from pure innovation to biosimilars to expand patient access and why availability is as critical as invention.
- From Empty Building to Phase 3: How she built a biosimilar company from scratch, advanced two products into Phase 3 in four years, and navigated a pivotal FDA meeting with 32 reviewers.
- End-to-End Biotech Leadership: Lessons from overseeing R&D, manufacturing build-outs, and global CDMO/CRO networks across Tanvex, Medivation, and Pfizer.
- Passion Over Paycheck: How prioritizing mission over short-term money at key career junctures ultimately benefited both her impact and financial outcomes.
- Culture, M&A, and Big Pharma: Experiences integrating Medivation into Pfizer, helping shape Pfizer’s oncology organization, and later stepping into large-scale leadership at Bayer.​
If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.
Subscribe to the Podcast:
Find our guest, Judy Chou at these links:
Find our host, Jon Chee, at these links:
Learn more about Excedr:
Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Resources & Articles:
​
Companies, Universities, & People mentioned:
​
Timestamps:
00:00 Intro
02:24 Becoming Employee Number One at Tanvex
04:57 Walking Into an Empty 50,000 Square Foot Facility Alone
06:29 Friend's Death from Lung Cancer: Why Biosimilars Matter
09:41 FDA Meeting: 32 Agents, One Scientist, Zero Animal Studies Required
17:05 Learning Every Part of Drug Discovery and Regulatory Process
20:19 Decision to Leave Tanvex Despite IPO Windfall
22:59 Following Passion Over Money: A Golden Timing Lesson
24:53 Joining Medivation and Building Tech Ops from Scratch
31:35 Five Bidders Competing: The $14.3 Billion Pfizer Acquisition
38:59 Bridging East Coast and West Coast Biotech Cultures at Pfizer
39:37 Joining Bayer: Leading 2,000 Employees Across Six Sites